Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUT5 | Q11128 | 1/20 | 0.76 |
| ▸ | TGM2 | P21980 | 1/20 | 0.70 |
| ▸ | KRAS | P01116 | 4/20 | 0.66 |
| ▸ | NT5E | P21589 | 1/20 | 0.66 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.62 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.61 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.60 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.60 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.60 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.60 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.57 |
| ▸ | SRC | P12931 | 1/20 | 0.57 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.57 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.57 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HINT1 | P49773 | 1/20 | 0.57 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.57 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29397556 | 1.00 | FUT5 (0.76) | FUT5TGM2KRASNT5EP2RY14 | |
| SCHEMBL14293772 | 1.00 | FUT5 (0.76) | FUT5TGM2KRASNT5EP2RY14 | |
| SCHEMBL14293912 | 1.00 | FUT5 (0.76) | FUT5TGM2KRASNT5EP2RY14 | |
| SCHEMBL24496886 | 1.00 | FUT5 (0.76) | FUT5TGM2KRASNT5EP2RY14 | |
| SCHEMBL9438541 | 1.00 | FUT5 (0.76) | FUT5TGM2KRASNT5EP2RY14 | |
| SCHEMBL25319857 | 1.00 | FUT5 (0.76) | FUT5TGM2KRASNT5EP2RY14 | |
| SCHEMBL14268500 | 1.00 | FUT5 (0.76) | FUT5TGM2KRASNT5EP2RY14 | |
| SCHEMBL2229602 | 1.00 | FUT5 (0.76) | FUT5TGM2KRASNT5EP2RY14 | |
| SCHEMBL30646155 | 1.00 | FUT5 (0.76) | FUT5TGM2KRASNT5EP2RY14 | |
| SCHEMBL29359526 | 1.00 | FUT5 (0.76) | FUT5TGM2KRASNT5EP2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230075422-A1 | USE OF FUCOSYLATION INHIBITOR FOR PRODUCING AFUCOSYLATED ANTIBODY | BRISTOL-MYERS SQUIBB COMPANY | 2023-03-09 | — | — | US | claimed |
| US-20250340651-A1 | ANTI-MICA/B ANTIBODIES WITH ENHANCED EFFECTOR FUNCTION AND METHODS OF USE | CULLINAN MICA CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250333531-A1 | HUMANIZED HH1 | NORDIC NANOVECTOR ASA (NO) | 2025-10-30 | — | — | US | disclosed |
| CN-120818475-A | Method for producing fucosylated oligosaccharides and use thereof | 柯泰亚生物科技(上海)有限公司 | 2025-10-21 | — | — | CN | disclosed |
| WO-2025214489-A1 | METHOD FOR PRODUCING FUCOSYLATED OLIGOSACCHARIDES AND USE THEREOF | 柯泰亚生物科技(上海)有限公司 | 2025-10-16 | — | — | WO | disclosed |
| EP-4619540-A1 | RECOMBINANT PRODUCTION OF PROTEIN HAVING XYLOSYLATED N-GLYCANS | Expres2ion Biotechnologies ApS (DK) | 2025-09-24 | — | — | EP | disclosed |
| US-20250230256-A1 | COMBINATION THERAPY OF BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD47 AND BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD3 | NOVIMMUNE S.A. (CH) | 2025-07-17 | — | — | US | disclosed |
| CN-114555817-B | Rhamnose polysaccharide | 敦提大学 | 2025-06-10 | — | — | CN | disclosed |
| EP-4561627-A1 | ANTI-MICA/B ANTIBODIES WITH ENHANCED EFFECTOR FUNCTION AND METHODS OF USE | Cullinan Mica Corporation (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250161428-A1 | PREVENTING/TREATING PSEUDOMONAS AERUGINOSA INFECTION | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2025-05-22 | — | — | US | disclosed |
| WO-2022195028-A2 | THERAPEUTIC BINDING MOLECULES | MEDIMMUNE LIMITED (GB) | 2022-09-22 | — | — | WO | disclosed |
| EP-4055055-A1 | BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD47 | LamKap Bio beta AG (CH) | 2022-09-14 | — | — | EP | disclosed |
| WO-2022184854-A2 | FORMULATIONS OF ACE2 FC FUSION PROTEINS | FORMYCON AG (DE) | 2022-09-09 | — | — | WO | disclosed |
| US-20220259629-A1 | RHAMNOSE-POLYSACCHARIDES | UNIVERSITY OF DUNDEE (GB) | 2022-08-18 | — | — | US | disclosed |
| US-20220195067-A1 | BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD47 | LAMKAP BIO BETA LTD (CH) | 2022-06-23 | — | — | US | disclosed |
| WO-2022130348-A1 | BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD47 | LAMKAP BIO BETA AG (CH) | 2022-06-23 | — | — | WO | disclosed |
| CN-114555817-A | Rhamnose polysaccharide | 敦提大学 | 2022-05-27 | — | — | CN | disclosed |
| EP-3983555-A1 | RHAMNOSE-POLYSACCHARIDES | University of Dundee (GB) | 2022-04-20 | — | — | EP | disclosed |
| US-20220112535-A1 | PRODUCTION OF PROTEIN WITH HUMANIZED N-GLYCOSYLATION IN INSECT CELLS | EXPRES2ION BIOTECHNOLOGIES APS (DK) | 2022-04-14 | — | — | US | disclosed |
| US-20220111027-A1 | GLYCO-ENGINEERED IMMUNIZATION ANTIGENS | EXPRES2ION BIOTECHNOLOGIES APS (DK) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230075422-A1 | USE OF FUCOSYLATION INHIBITOR FOR PRODUCING AFUCOSYLATED ANTIBODY | GMDS, GPI, FUCA1 | FUT5 28/4885TGM2 837/4885KRAS 643/4885 |
| US-20250161428-A1 | PREVENTING/TREATING PSEUDOMONAS AERUGINOSA INFECTION | SIGLEC7, CD47, SELP | FUT5 6/4885TGM2 471/4885KRAS 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.